TWI262925B - GLP-1 analogues - Google Patents

GLP-1 analogues

Info

Publication number
TWI262925B
TWI262925B TW088121393A TW88121393A TWI262925B TW I262925 B TWI262925 B TW I262925B TW 088121393 A TW088121393 A TW 088121393A TW 88121393 A TW88121393 A TW 88121393A TW I262925 B TWI262925 B TW I262925B
Authority
TW
Taiwan
Prior art keywords
analogues
glp
peptide
glucagon
pharmaceutically
Prior art date
Application number
TW088121393A
Other languages
English (en)
Inventor
Zheng-Xin Dong
David H Coy
Original Assignee
Sod Conseils Rech Applic
Admin Tulane Education Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic, Admin Tulane Education Fund filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of TWI262925B publication Critical patent/TWI262925B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
TW088121393A 1998-12-07 2000-01-07 GLP-1 analogues TWI262925B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20683398A 1998-12-07 1998-12-07
US11118698P 1998-12-07 1998-12-07

Publications (1)

Publication Number Publication Date
TWI262925B true TWI262925B (en) 2006-10-01

Family

ID=26808707

Family Applications (2)

Application Number Title Priority Date Filing Date
TW088121393A TWI262925B (en) 1998-12-07 2000-01-07 GLP-1 analogues
TW095106593A TWI339208B (en) 1998-12-07 2000-01-07 Glp-1 analogues

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW095106593A TWI339208B (en) 1998-12-07 2000-01-07 Glp-1 analogues

Country Status (21)

Country Link
US (2) US7368427B1 (zh)
EP (2) EP1992641A3 (zh)
JP (3) JP2002538081A (zh)
KR (1) KR100458748B1 (zh)
CN (2) CN101108878B (zh)
AT (1) ATE394423T1 (zh)
AU (1) AU770609B2 (zh)
BR (1) BR9916027A (zh)
CA (1) CA2352573C (zh)
CZ (2) CZ303120B6 (zh)
DE (1) DE69938669D1 (zh)
DK (1) DK1137666T5 (zh)
ES (1) ES2302390T3 (zh)
HU (1) HUP0104579A3 (zh)
IL (2) IL143481A0 (zh)
NO (2) NO330293B1 (zh)
PL (3) PL393611A1 (zh)
PT (1) PT1137666E (zh)
RU (1) RU2208015C2 (zh)
TW (2) TWI262925B (zh)
WO (1) WO2000034332A1 (zh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
EP1992641A3 (en) * 1998-12-07 2009-07-29 Ipsen Pharma GLP-1 analogues
WO2002010195A2 (en) * 2000-08-02 2002-02-07 Theratechnologies Inc. Modified peptides with increased potency
JP5161412B2 (ja) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
DE60142351D1 (de) 2000-10-20 2010-07-22 Amylin Pharmaceuticals Inc Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid
ATE416784T1 (de) 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
AU2012202081B2 (en) * 2001-07-31 2014-09-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 Exendin-4 peptide analogs and uses thereof
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
PL377687A1 (pl) * 2001-10-18 2006-02-06 Bristol-Myers Squibb Company Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą
KR101065471B1 (ko) 2002-07-23 2011-09-16 입센 파마 에스.에이.에스 그렐린 유사체
EP1583549A4 (en) * 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
CA2513307A1 (en) * 2003-02-19 2004-09-02 Zheng Xin Dong Analogues of glp-1
KR20060013369A (ko) * 2003-03-28 2006-02-09 독립행정법인농업생물자원연구소 재조합 단백질이 다량 생산되는 식물 저장 기관의 생산방법 및 신규 재조합 단백질
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
EP1711523B1 (en) * 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
EP1694278A4 (en) * 2003-12-16 2009-08-12 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
JP2007537149A (ja) * 2004-01-08 2007-12-20 セラテクノロジーズ インコーポレイテッド 長時間作用性のグルカゴン様ペプチド−１類似体
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
ATE553124T1 (de) * 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
WO2007051987A1 (en) * 2005-11-01 2007-05-10 Activotec Spp Limited Insulinotropic compounds and uses thereof
EP1968644B1 (en) 2005-12-16 2012-06-27 Nektar Therapeutics Polymer conjugates of glp-1
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
SG177953A1 (en) * 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
US20100256056A1 (en) * 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
CN102088989B (zh) * 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
US20110269680A1 (en) * 2008-12-29 2011-11-03 Panacea Biotec Limited Glp-1 analogs and uses thereof
MX2012014576A (es) * 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012166951A1 (en) 2011-05-31 2012-12-06 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators
RU2634896C2 (ru) 2011-12-12 2017-11-08 Селджин Интернэшнл Ii Сарл Новые модуляторы рецептора glp-1
CN102584982B (zh) * 2012-02-10 2014-02-05 深圳翰宇药业股份有限公司 一种纯化固相合成利拉鲁肽粗肽的方法
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
PE20151770A1 (es) * 2013-05-28 2015-12-11 Takeda Pharmaceutical Compuesto peptidico
CN103285379A (zh) * 2013-06-09 2013-09-11 南方医科大学 Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途
EP3008056B8 (en) 2013-06-11 2021-03-03 Receptos Llc Novel glp-1 receptor modulators
MX2017000972A (es) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
JP2017538711A (ja) 2014-12-10 2017-12-28 セルジーン インターナショナル ツー エスエーアールエル Ｇｌｐ−１レセプターモジュレーター
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2017112889A1 (en) 2015-12-23 2017-06-29 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
NZ743474A (en) 2015-12-23 2023-03-31 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
CN109477094B (zh) 2016-05-24 2022-04-26 武田药品工业株式会社 肽化合物
EP3463415A4 (en) * 2016-06-02 2020-03-25 Indiana University Research & Technology Corporation WATER-SOLUBLE AND CHEMICALLY STABLE GLUCAGON PEPTIDES
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
CN109942696A (zh) * 2017-12-21 2019-06-28 中国药科大学 长效化胰高血糖素样肽－1（glp－1）类似物及其应用
CN116970062B (zh) * 2022-04-29 2024-04-09 南京知和医药科技有限公司 一种超长效glp-1多肽衍生物及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1539498A (en) 1925-05-26 And fifteen
EP0512042B1 (en) * 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
KR0154880B1 (ko) * 1992-06-15 1998-10-15 피터 알.셰어러 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
JP2001503963A (ja) * 1996-02-06 2001-03-27 イーライ・リリー・アンド・カンパニー 糖尿病治療
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998043658A1 (en) * 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
EP1992641A3 (en) * 1998-12-07 2009-07-29 Ipsen Pharma GLP-1 analogues
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
AU1269501A (en) 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration

Also Published As

Publication number Publication date
JP2002538081A (ja) 2002-11-12
BR9916027A (pt) 2001-08-28
EP1137666A1 (en) 2001-10-04
ES2302390T3 (es) 2008-07-01
KR20010102953A (ko) 2001-11-17
DK1137666T3 (da) 2008-09-08
HUP0104579A3 (en) 2002-05-28
WO2000034332A1 (en) 2000-06-15
DK1137666T5 (da) 2009-10-05
AU1751200A (en) 2000-06-26
CZ303120B6 (cs) 2012-04-11
IL143481A0 (en) 2002-04-21
IL143481A (en) 2010-02-17
PL393611A1 (pl) 2011-05-09
JP2006077022A (ja) 2006-03-23
CN101108878B (zh) 2012-08-29
CA2352573A1 (en) 2000-06-15
EP1992641A2 (en) 2008-11-19
NO20100307L (no) 2001-08-06
ATE394423T1 (de) 2008-05-15
TWI339208B (en) 2011-03-21
US20090149378A1 (en) 2009-06-11
CN101108878A (zh) 2008-01-23
EP1992641A3 (en) 2009-07-29
KR100458748B1 (ko) 2004-12-03
US7368427B1 (en) 2008-05-06
NO20012787D0 (no) 2001-06-06
PT1137666E (pt) 2008-06-02
PL208751B1 (pl) 2011-06-30
EP1137666B1 (en) 2008-05-07
HUP0104579A2 (hu) 2002-04-29
NO330293B1 (no) 2011-03-21
PL205713B1 (pl) 2010-05-31
CN1342166A (zh) 2002-03-27
RU2208015C2 (ru) 2003-07-10
CN100334109C (zh) 2007-08-29
EP1137666B9 (en) 2009-04-01
AU770609B2 (en) 2004-02-26
CA2352573C (en) 2012-04-10
CZ303399B6 (cs) 2012-08-29
NO20012787L (no) 2001-08-06
JP2010001301A (ja) 2010-01-07
TW200628489A (en) 2006-08-16
CZ20011895A3 (cs) 2001-12-12
DE69938669D1 (de) 2008-06-19

Similar Documents

Publication Publication Date Title
TWI262925B (en) GLP-1 analogues
SG125915A1 (en) Analogues of glp-1
WO2005058252A3 (en) Glp-1 pharmaceutical compositions
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
WO2004074315A3 (en) Analogues of glp-1
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
UA35636C2 (uk) Поліпептид, який має активність легеневої поверхнево-активної речовини, та фармацевтична композиція для лікування респіраторного дистрес-синдрому у ссавців
WO2003061362A3 (en) Methods and compositions for treating polycystic ovary syndrome
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
TW200740456A (en) GLP-1 pharmaceutical compositions
EP2210900A3 (en) Analogues of GLP-1
EP1359159A3 (en) Analogues of GLP-1
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
UA88862C2 (en) Glucagon-like peptide-1 analogs

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees